drugset / Trial / NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2
Recruiting
147 enrolled
Children's Oncology Group
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegavivint | Small molecule | 4 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 5 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 6.5 mg/kg | Intravenous |
| Subject | Tegavivint | Small molecule | 8 mg/kg | Intravenous |